MIRA INFORM REPORT

 

 

Report Date :

05.07.2012

 

IDENTIFICATION DETAILS

 

Name :

SANOFI AVENTIS KK

 

 

Registered Office :

Tokyo Operation Tower, 3-20-2 Nishishinjuku Shinjukuku Tokyo 163-1488

 

 

Country :

Japan

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

January 2006

 

 

Com. Reg. No.:

0111-01-037279

 

 

Legal Form :

Limited Company

 

 

Line of Business :

Manufacturer of pharmaceuticals, medical equipment/apparatus

 

 

No. of Employees :

3,000

 

RATING & COMMENTS

 

MIRA’s Rating :

A

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

 

Status :

Good

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

Company name

 

SANOFI AVENTIS KK

 

 

REGD NAME 

 

Sanofi Aventis KK

 

 

MAIN OFFICE

 

Tokyo Operation Tower, 3-20-2 Nishishinjuku Shinjukuku Tokyo 163-1488 JAPAN

Tel: 03-6301-3000

 

URL:                 http://www.sanofi-aventis.co.jp

E-Mail address:            (thru the URL)

 

 

ACTIVITIES  

 

Mfg of pharmaceuticals, medical equipment/apparatus%

 

 

BRANCHES

 

Osaka, Sapporo, Sendai, Yokohama, Nagoya, Kyoto, Kobe, other (Tot 19)

 

 

FACTORIES

 

Kawagoe (Saitama)

 

 

OFFICERS

 

JEZ MOULDING, PRES              Hanspecter Spek, dir

Jean-Michel Demeure, dir                       Patrick Chocat, dir

Toshinaka Suzuki, dir                 Kazuji Tanaka, dir                     

 

Yen Amount:     In million Yen, unless otherwise stated

 

SUMMARY

 

FINANCES        FAIR                             A/SALES          Yen 269,200 M

PAYMENTS No Complaints   CAPITAL           Yen 12,714 M

TREND UP                                WORTH            Yen 48,200 M

STARTED         2006                             EMPLOYES      3,000

 

 

COMMENT

 

MFG OF PHARMACEUTICALS, MEDICAL INSTRUMENTS, OWNED BY THE FRENCH CAPITAL

 

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

 

 

HIGHLIGHTS

           

The subject company was established by Sanofi-Aventis Participations, France, as its marketing arm in Japan.  The subject specializes in mfg pharmaceuticals, medical instruments, equipment, others: for circulatory organs, thrombosis, central nervous systems, cancer, other.  Clients include Nichiiko, hospitals, other, nationwide.

 

 

FINANCIAL INFORMATION

           

The sales volume for Dec/2011 fiscal term amounted to Yen 269,200 million, a 14% up from Yen 235,900 million in the previous term.  Generic drugs rose.  The recurring profit was posted at Yen 56,800 million and the net profit at Yen 28,000 million, respectively, compared with Yen 57,000 million recurring profit and Yen 34,900 million net profit, respectively, a year ago.

 

For the current term ending Dec 2012 the recurring profit is projected at Yen 57,000 million and the net profit at Yen 30,000 million, respectively, on a 10% rise in turnover, to Yen 296,000 million.  Business is seen expanding steadily. 

 

The financial situation is considered FAIR and good for ORDINARY business engagements. 

 

 

REGISTRATION

 

Date Registered:  Jan 2006

Regd No.:         0111-01-037279 (Tokyo-Shinjukuku)

Legal Status:      Limited Company (Kabushiki Kaisha)

Authorized:         254,280 shares

Issued:                254,280 shares

Sum:                   Yen 12,714 million

Major shareholders (%): Sanofi-Aventis Participations (France) (100)

 

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: Manufactures and imports pharmaceuticals, medical equipment & apparatus, centrally for: circulatory organs, thrombosis, central nervous systems, cancers, others (--100%)

 

Clients: [Hospitals, mfrs, wholesalers] Suzuken Co, Alfresa Corp, Alfresa Pharma, Chugai Pharmaceutical, Mediceo, Eisai Co, other 

            No. of accounts: 500

            Domestic areas of activities: Nationwide

 

Suppliers [Mfrs, wholesalers] Sanofi-Aventis Group firms, Ajinomoto, Fuji Seal, other

 

Payment record: No Complaints

 

Location: Business area in Tokyo.  Office premises at the caption address are leased and maintained satisfactorily.

 

Bank References:

MUFG (H/O)

SMBC (Akasaka)

Relations: Satisfactory

 

FINANCES

(In Million Yen)

 

       Terms Ending:

31/12/2012

31/12/2011

31/12/2010

31/12/2009

Annual Sales

　

296,000

269,200

235,900

219,300

Recur. Profit

　

57,000

56,800

57,000

52,700

Net Profit

　

30,000

28,000

34,900

29,800

Total Assets

　

　

2,225,000

205,300

197,700

Current Assets

　

　

185,800

159,100

154,300

Current Liabs

　

　

162,500

137,600

133,900

Net Worth

　

　

48,200

56,200

50,300

Capital, Paid-Up

　

　

12,714

12,714

12,714

Div.P.Share(¥)

　

　

0.00

0.00

0.00

<Analytical Data>

(%)

(%)

(%)

(%)

    S.Growth Rate

9.96

14.12

7.57

12.06

    Current Ratio

 

..

114.34

115.63

115.24

    N.Worth Ratio

..

2.17

27.37

25.44

    R.Profit/Sales

 

19.26

21.10

24.16

24.03

    N.Profit/Sales

10.14

10.40

14.79

13.59

    Return On Equity

..

58.09

62.10

59.24

 

Notes: Forecast (or estimated) figures for the 31/12/2012 fiscal term.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.54.55

UK Pound

1

Rs.85.48

Euro

1

Rs.68.70

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.